CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y12*2 AND CYP2Y12*3 POLYMORPHISMS

CLOPIDOGREL RESPONSE IN ACUTE CORONARY SYNDROME PATIENTS WITH CYP2Y122 AND CYP2Y123 POLYMORPHISMS

Aim. This study aimed to look at the characteristics of the P2Y12 reactivity unit (PRU) in 30 Minang acute coronary syndrome (ACS) patients in Dr. M. Djamil Hospital, Padang, Indonesia.Material and methods. This research was a cross-sectional study conducted in September 2016. The effectiveness of c...

Full description

Bibliographic Details
Main Authors:	R. Rahmatini, G. Aliska, M. Syafri, A. Achyar
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2018-04-01
Series:	Российский кардиологический журнал
Subjects:	acute coronary syndrome clopidogrel cyp2c19 polymorphism pru
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/2659

Similar Items

CYP2C19*1 and CYP2C19*2 Polymorphism in Turkish Patients Being Diagnosed with Stable Coronary Artery Disease and Using Clopidogrel
by: Ramazan Sabırlı, et al.
Published: (2021-03-01)

Cytochrome P-450 CYP2C19 genetic polymorphism and its relation with clopidogrel resistance
by: Usman Nawaz, et al.
Published: (2023-11-01)

microRNA-605 rs2043556 polymorphisms affect clopidogrel therapy through modulation of CYP2B6 and P2RY12 in acute coronary syndrome patients
by: Wan-Lu Zhou, et al.
Published: (2020-10-01)

The correlation between CYP2C19 Polymorphisms and recurrent risk in Patients with Ischemic Stroke treated with Clopidogrel in Kurdistan region-Iraq
by: Hind Salim Jardaq, et al.
Published: (2022-12-01)

Influence of CYP450 Enzymes and ABCB1 Polymorphisms on Clopidogrel Response in Moroccan Patients with Acute Coronary Syndromes
by: Mouhrach I, et al.
Published: (2023-10-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Effects of Cyp2c19 and P2y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel After Acute Ischemic Cerebrovascular Disease
by: Sen H. M., et al.
Published: (2014-12-01)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
by: Seyed abbas Mirabbasi, et al.
Published: (2017-07-01)

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt
by: Ahmed Shawky, et al.
Published: (2023-05-01)

Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
by: Daniele Jones, et al.
Published: (2024-01-01)

miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome
by: Zhen-Zhen Mo, et al.
Published: (2023-02-01)

THE ROLE OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER THE EMERGENCE OF MORE POWERFUL INHIBITORS OF P2Y12 RECEPTOR
by: S. R. Gilyarevsky, et al.
Published: (2014-07-01)

THE ROLE OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME AFTER THE EMERGENCE OF MORE POWERFUL INHIBITORS OF P2Y12 RECEPTOR
by: S. R. Gilyarevsky, et al.
Published: (2014-07-01)

CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis
by: Ziwei Xi, et al.
Published: (2019-02-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

Impact of CYP2C19 variants on clinical efficacy of clopidogrel and one-year clinical outcomes in coronary heart patients undergoing percutaneous coronary intervention
by: Hong Sun, et al.
Published: (2016-11-01)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
by: Sherry-Ann Brown, et al.
Published: (2018-01-01)

A Pharmacogenetic Study of <i>CYP2C19</i> in Acute Coronary Syndrome Patients of Colombian Origin Reveals New Polymorphisms Potentially Related to Clopidogrel Therapy
by: Mariana Angulo-Aguado, et al.
Published: (2021-05-01)

Substantiation of a clopidogrel metabolism-associated gene (CYP2C19) variation among healthy individuals
by: Anshu Kumar Yadav, et al.
Published: (2023-09-01)

The association between CYP2C19 genetic polymorphism and prognosis in patients receiving endovascular therapy
by: Wei Li, et al.
Published: (2024-01-01)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
by: Amber L. Beitelshees, et al.
Published: (2022-02-01)

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
by: Po-Wei Chen, et al.
Published: (2020-06-01)

Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease
by: Yujing Cheng, et al.
Published: (2023-01-01)

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China
by: Yijun Mo, et al.
Published: (2023-02-01)

NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: K. B. Mirzaev, et al.
Published: (2018-03-01)

Investigation of cytochrome p450 CYP1A2, CYP2D6, CYP2E1 and CYP3A4 gene expressions and polymorphisms in alcohol withdrawal (eng)
by: Nazife Taşçıoğlu, et al.
Published: (2021-09-01)

The combination of CYP2C19 polymorphism and inflammatory cell ratios in prognosis cardiac adverse events after acute coronary syndrome
by: Toan Hoang Ngo, et al.
Published: (2023-12-01)

Co-Existence of CYP2C19*1/*2 and ABCB1c.3435 CT Genotype has a Potential Impact on Clinical Outcome in CAD Patients Treated with Clopidogrel
by: Nestorovska KA, et al.
Published: (2024-03-01)

Serotonin syndrome caused by a CYP2C19-mediated interaction between low-dose escitalopram and clopidogrel: a case report
by: Jianhong Wu, et al.
Published: (2023-10-01)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2022-04-01)

Clopidogrel response in acute coronary syndrome : clinical implications & emerging therapies /
by: Miguel Castro, Antonio de
Published: (2011)

CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel
by: Yu-Wei Chen, et al.
Published: (2022-08-01)

Association of ABCC2 polymorphism with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention
by: Lida Chen, et al.
Published: (2022-10-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Response to Duloxetine in Patients with Major Depression
by: Julian Maciaszek, et al.
Published: (2023-08-01)

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)
by: Mohammed Ahmed Akkaif, et al.
Published: (2021-04-01)

Genetic polymorphism of clopidogrel metabolism related gene CYP2C19 gene in Chinese from Foshan area of Guangdong Province
by: Xiao-wen Yuan, et al.
Published: (2022-12-01)

Regional aspects of associations of the CYP2C19 gene polymorphism with coronary atherosclerosis in acute coronary syndrome
by: K. Yu. Nikolaev, et al.
Published: (2018-11-01)

Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis
by: Mohitosh Biswas, et al.
Published: (2021-07-01)

METTL3-mediated methylation of CYP2C19 mRNA may aggravate clopidogrel resistance in ischemic stroke patients
by: Tan Quandan, et al.
Published: (2024-02-01)